Retatrutide — Investigational Triple Agonist
Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist. Not FDA-approved; not commercially available.
Evidence-based answer
Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist. Not FDA-approved; not commercially available.
Regulatory status: Retatrutide is investigational and is not FDA approved. Products sold online as retatrutide are not the sponsor’s approved commercial drug because no approved commercial product exists.
How it works
Retatrutide is designed to activate GIP, GLP-1 and glucagon receptors. The glucagon component may affect energy expenditure while incretin activity affects appetite and glucose metabolism.
Mechanism is context, not proof. A defensible claim requires human outcome data for the exact molecule, formulation, dose and population. Receptor activity alone cannot establish how much weight a patient will lose, whether an injury will heal or whether a compounded vial has the identity and potency of a trial product.
What the clinical evidence shows
A phase 2 obesity trial reported large mean reductions at higher doses over 48 weeks. Phase 2 data do not establish an approved dose, manufacturing standard or long-term benefit-risk profile; phase 3 confirmation is required.
| Study or evidence level | Population | Intervention | Main result | Interpretation |
|---|---|---|---|---|
| Evidence grade | Varies by molecule | Exact product and route required | See primary sources | Do not extrapolate animal or mechanism data to human outcomes |
Clinical-use framework
No FDA-approved dose or self-use protocol exists. Research-use products should not be injected into humans.
A safe plan includes medical history, medication reconciliation, pregnancy screening where relevant, contraindication review, a written titration or administration schedule, missed-dose instructions, side-effect escalation and follow-up. Laboratory testing is individualized; a universal panel is not evidence-based for every patient, but clinicians may order testing based on symptoms, comorbidities and the medicine considered.
How to evaluate an online program
- Identify the legal entities. The marketing company, prescribing practice and dispensing pharmacy may be different organizations.
- Confirm the clinician. Look for a full name, credential, NPI where applicable and authority to practice in the patient’s state.
- Read the prescription label. Verify the exact drug, salt or base, concentration, directions, facility and beyond-use date.
- Normalize cost. Add medication, membership, visits, labs, supplies, shipping and dose surcharges.
- Match the evidence. Ask whether the offered dose and route were studied for the claimed outcome.
- Review continuity. Understand refills, cold-chain handling, replacement, pharmacy changes and cancellation.
Safety
Gastrointestinal adverse effects were common in early trials, and heart-rate changes require continued study. Long-term cardiovascular, pancreatic, gallbladder and lean-mass outcomes remain incompletely characterized.
This page is educational and does not replace diagnosis or individualized prescribing. Severe symptoms, suspected overdose or a serious allergic reaction require urgent in-person evaluation.
Frequently asked questions
Is retatrutide FDA approved?
Retatrutide is investigational and is not FDA approved. Products sold online as retatrutide are not the sponsor’s approved commercial drug because no approved commercial product exists.
What is the strongest evidence for retatrutide?
A phase 2 obesity trial reported large mean reductions at higher doses over 48 weeks. Phase 2 data do not establish an approved dose, manufacturing standard or long-term benefit-risk profile; phase 3 confirmation is required.
Can a compounded or microdose product claim the same trial result?
Not automatically. The trial result applies most directly to the studied product, dose, titration, population and duration. A different formulation, route or lower dose requires its own evidence.
What should be verified before treatment?
Verify the exact product, indication, prescriber, pharmacy, concentration, dose schedule, recurring cost, commitment, follow-up plan and urgent-care instructions.
Primary sources
- Retatrutide phase 2 trial, NEJM Primary clinical or regulatory source
- ClinicalTrials.gov Primary clinical or regulatory source
Provider marketing can document what is offered; it is not used as proof of safety or comparative effectiveness. Evidence was reviewed through July 12, 2026.